FI3713572T3 - Takykardian hoito - Google Patents

Takykardian hoito

Info

Publication number
FI3713572T3
FI3713572T3 FIEP18804633.8T FI18804633T FI3713572T3 FI 3713572 T3 FI3713572 T3 FI 3713572T3 FI 18804633 T FI18804633 T FI 18804633T FI 3713572 T3 FI3713572 T3 FI 3713572T3
Authority
FI
Finland
Prior art keywords
yhdiste
joka
methyl
ääää
phenyl
Prior art date
Application number
FIEP18804633.8T
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Jan Magnus Aronsen
Jonas Skogestad
Original Assignee
Oslo Univ Hospital Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oslo Univ Hospital Hf filed Critical Oslo Univ Hospital Hf
Application granted granted Critical
Publication of FI3713572T3 publication Critical patent/FI3713572T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP18804633.8T 2017-11-23 2018-11-23 Takykardian hoito FI3713572T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17203377 2017-11-23
PCT/EP2018/082450 WO2019101970A1 (en) 2017-11-23 2018-11-23 Treatment of tachycardia

Publications (1)

Publication Number Publication Date
FI3713572T3 true FI3713572T3 (fi) 2025-09-09

Family

ID=60452486

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18804633.8T FI3713572T3 (fi) 2017-11-23 2018-11-23 Takykardian hoito

Country Status (12)

Country Link
US (2) US11419874B2 (enExample)
EP (1) EP3713572B1 (enExample)
JP (2) JP2021504466A (enExample)
CN (1) CN111447930A (enExample)
AU (1) AU2018371216B2 (enExample)
CA (1) CA3083176A1 (enExample)
DK (1) DK3713572T3 (enExample)
ES (1) ES3039584T3 (enExample)
FI (1) FI3713572T3 (enExample)
PL (1) PL3713572T3 (enExample)
PT (1) PT3713572T (enExample)
WO (1) WO2019101970A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11219642B1 (en) * 2020-09-01 2022-01-11 Catherine Lueninghoener Methods and compositions for treating heart conditions
CN113063804B (zh) * 2021-03-16 2022-07-15 太原科技大学 一种基于图像处理的热切机视觉系统自动定位方法
TWI827037B (zh) * 2021-05-07 2023-12-21 美商默沙東有限責任公司 作為nav1.8抑制劑之環烷基3-側氧基哌甲醯胺及環雜烷基3-側氧基哌甲醯胺

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
NZ540167A (en) 2002-10-30 2007-06-29 Neuro3D Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
EP1601675A1 (en) * 2003-03-04 2005-12-07 ALTANA Pharma AG Purin-6-one-derivatives
JP2007504117A (ja) 2003-08-28 2007-03-01 アルタナ　ファルマ　アクチエンゲゼルシャフト 肺サーファクタントとｐｄｅ２阻害剤とを含有する組成物
WO2005035505A2 (en) 2003-09-30 2005-04-21 Artesian Therapeutics, Inc. Compounds with phosphodiesterase inhibiting and calcium channel blocking activities
WO2005041957A1 (en) 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
DK1697356T3 (da) 2003-12-16 2009-01-12 Pfizer Prod Inc Pyrido[2,3-d]pyrimidin-2,4-diaminer som PDE 2-inhibitorer
EP1548011A1 (en) 2003-12-23 2005-06-29 Neuro3D Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof
DE602005021894D1 (de) * 2004-09-02 2010-07-29 Nycomed Gmbh Triazolophthalazine
EA012505B1 (ru) 2005-01-05 2009-10-30 Никомед Гмбх Триазолофталазины в качестве ингибиторов pde-2
JP5130053B2 (ja) 2005-01-05 2013-01-30 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング トリアゾロフタラジン
EP1749824A1 (en) 2005-08-03 2007-02-07 Neuro3D Benzodiazepine derivatives, their preparation and the therapeutic use thereof
DE102006048693A1 (de) 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition der PDE2A
US20110190373A1 (en) * 2008-05-05 2011-08-04 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
WO2010054253A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Triazine derivatives as inhibitors of phosphodiesterases
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
WO2012114222A1 (en) 2011-02-23 2012-08-30 Pfizer Inc. IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
EP2718295A1 (en) 2011-06-07 2014-04-16 Pfizer Inc Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
ES2575092T3 (es) 2011-06-27 2016-06-24 Janssen Pharmaceutica, N.V. Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina
MX361539B (es) 2012-04-25 2018-12-10 Takeda Pharmaceuticals Co Compuesto heterociclico nitrogenado.
WO2014010732A1 (ja) 2012-07-13 2014-01-16 武田薬品工業株式会社 複素環化合物
US20140045856A1 (en) 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
EP3026051A4 (en) 2013-07-24 2017-03-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2017114764A (ja) * 2014-04-25 2017-06-29 武田薬品工業株式会社 片頭痛治療剤
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物

Also Published As

Publication number Publication date
AU2018371216B2 (en) 2024-09-19
PT3713572T (pt) 2025-08-28
DK3713572T3 (da) 2025-08-25
CN111447930A (zh) 2020-07-24
EP3713572B1 (en) 2025-07-30
JP2021504466A (ja) 2021-02-15
EP3713572A1 (en) 2020-09-30
US20220362251A1 (en) 2022-11-17
ES3039584T3 (en) 2025-10-22
AU2018371216A1 (en) 2020-06-04
WO2019101970A1 (en) 2019-05-31
US11419874B2 (en) 2022-08-23
CA3083176A1 (en) 2019-05-31
JP2024012483A (ja) 2024-01-30
PL3713572T3 (pl) 2025-09-22
US20200345744A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
FI3713572T3 (fi) Takykardian hoito
CN1420730A (zh) 附件用一次性指套
Elattar et al. Reactivity of indolizines in organic synthesis
JP2009534368A5 (enExample)
TW200502230A (en) Dual nk1/nk3 derivatives
IE890026L (en) Substituted pyrrole, pyrazole and triazole angiotensin II antagonists
CA2649775A1 (en) Pyridine[3,4-b]pyrazinones
NZ600926A (en) Nitrogen-containing heterocyclic compound and agricultural/horticultural germicide
CA2161857A1 (en) Oxazolidinone derivatives as adhesion receptor antagonists
SG189499A1 (en) Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer's disease
JP7679351B2 (ja) 除草剤としての置換ピリダジノン
GEP20125637B (en) Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
PL1756086T3 (pl) Pirydyn-4-ylo-etynylo-imidazole i pirazole jako antagoniści receptora mGlu5
CN102657195A (zh) 一种带消毒功能的洗手液或洗衣液的添加剂及其制备方法
JP7693645B2 (ja) 除草剤としての置換ピリダジノン
MA33385B1 (fr) Acide trans-4-[[(5s)-5-[[[3,5-bis (trifluorométhyl) phényl] méthyl] (2-méthyl-2h-tétrazol-5-yl) amino]-2,3,4,5-tétrahydro-7,9-diméthyl-1h-1-benzazépin-1-yl] méthyl]-cyclohexane carboxylique
AU2005300691A1 (en) Combinations of nicotinic acetylcholine alpha 7 receptor agonists
NO20070148L (no) Nye oksabispidinforbindelser og deres anvendelse ved behandling av forstyrrelser i hjerterytmen
WO2002028863A8 (en) New oxabispidine compound useful in the treatment of cardiac arrhythmias
GB0003256D0 (en) Heterocyclic compounds and their therapeutic use
US2999047A (en) Bactericidal composition
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
EP1028113A4 (en) HETEROCYCLIC DERIVATIVES OF BENZENE IN FUSION AND THEIR USE
JPH01308253A (ja) ２―（３―ピリジル）プロパンニトリル誘導体、その製法及びその用途
HUT70173A (en) 3-benzoyl-3,7-diazabicyclo[3.3.1] nonane compounds and pharmaceutical compositions containing them